In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Intact Vascular closes $38.9mm Series B; closes round at $46mm

Executive Summary

Intact Vascular Inc. (minimally invasive surgical devices for peripheral vascular disease) raised $38.9mm in its Series B financing led by new backer New Enterprise Associates, which adds a board member and was joined by returning shareholders Quaker Partners, HIG BioVentures, and others. Funds will help the company finish developing and gain FDA approval for its Tack Endovascular System for angioplasty in PAD patients.

Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies